Sun pharma were pioneers among Indian pharmaceutical companies to see tremendous value in investing in research & development (R&D). Their early investments in R&D, beginning three decades ago, enabled them to make technology their key differentiator and develop a basket of robust products for diverse markets across the world. Their core strength lies in their ability to excel in developing generics and technologically complex products through focused teams in formulations, process chemistry and analytical development. Sun pharma have the capability to deliver quality products within established timelines, at low costs and without compromising on quality. Sun pharma have around 2000 research scientists working in multiple R&D centres equipped with cutting-edge enabling technologies for research. Their scientists have expertise in developing generics, difficult to make technology intensive products, Active Pharmaceutical Ingredients (APIs), Novel Drug Delivery Systems (NDDS) and New Chemical Entities (NCEs). Their capabilities span the development of differentiated products, such as liposomal products, inhalers, lyophilised injections, nasal sprays, besides developing controlled release dosage forms. Over the years, Sun pharma have developed expertise and gathered experience in performing pharmacokinetic and bioequivalence studies to facilitate the introduction of generic or branded generic drugs into the international market. Their 408-bed clinical pharmacology unit with expert staff works on bioequivalence/bioavailability studies in compliance with GCP. Facilities include a full-fledged site for Phase I clinical studies. Their CPU has been audited by US FDA, ANVISA, MHRA, and DCGI among others.